Upregulating microRNA-373-3p promotes apoptosis and inhibits metastasis of hepatocellular carcinoma cells.

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies in the digestive system. Abnormal miR-373-3p and TFAP4 expressions are critical in many malignant tumors, but it is unclear whether they work in the context of HCC. qRT-PCR measured miR-373-3p expression in HCC tissues and adjacent normal tissues. Flow cytometry and Western blot analyzed cell apoptosis. EMT, Transwell, and wound healing assay examined HCC cell migration and EMT, respectively. Western blot determined the profile of TFAP4/PI3K/AKT. IHC detected Ki67, E-cadherin, and vimentin in the tumor tissues. Moreover, the downstream target of miR-373-3p was predicted using the database. Dual luciferase activity assay and RIP verified the binding correlation between TFAP4 and miR-373-3p. In HCC tissues and cell lines, miR-373-3p was downregulated, and its overexpression stepped up HCC cell apoptosis and suppressed migration and EMT. Furthermore, miR-373-3p overexpression elevated Bax and caspase 3 expressions and attenuated Bcl2's level. A xenograft tumor experiment in nude mice unveiled that miR-373-3p overexpression dampened tumor growth and proliferation. miR-373-3p cramped PI3K/AKT pathway activation. miR-373-3p negatively modulated TFAP4, and TFAP4 overexpression inverted miR-373-3p-mediated anti-tumor effects. Additionally, TFAP4 enhanced IGF1 expression, and promoted IGF1R-PI3K/AKT pathway activation. Collectively, miR-373-3p functions as an anti-tumor gene in HCC by inhibiting TFAP4/PI3K/AKT pathway.

Introduction

Primary liver cancer is ranked the fifth most prevailing malignancy across the globe, especially in Africa and East Asia. About 90% of the pathological type is hepatocellular carcinoma (HCC) [1]. Risk factors for HCC encompass viral hepatitis (particularly HBV and HCV), excessive drinking, aflatoxin poisoning, and nonalcoholic fatty liver disease [2,3]. Surgical resection is the primary treatment for liver cancer, but it is not efficacious enough for most patients with advanced liver cancer [4]. Apart from huge progress made in liver cancer treatment in the past years, some emerging technologies like immune checkpoint therapy and radiofrequency ablation have also entered the clinic [5,6]. Nevertheless, some patients would develop strong resistance to those therapies, even metastasis and recurrence. Hence, the development of new strategies for HCC treatment is warranted for patients’ survival and prognosis.

MicroRNAs (miRNAs) are known as endogenous conserved small molecules (19–25 nucleotides in length). Aberrant miRNA expressions contribute greatly to tumor cell proliferation, differentiation, migration, and apoptosis [7,8]. miR-1254 upregulation can curb Hippo Yap signaling pathway activation by targeting PAX5, thereby bolstering HCC cell proliferation, migration, and invasion [9]. miR-1301 targets BCL9 and impedes the Wnt/β-catenin signaling pathway, thus weakening HCC cell migration, invasion, epithelial mesenchymal transition, and angiogenesis [10]. miR-373-3p, a member of the miRNA family, plays a significant part in diverse cancers. For instance, lncRNA EIF3J-AS1 targets miR-373-3p, upregulates AKT1 expression, and facilitates esophageal cancer progression [11]. miR-373-3p, highly expressed in clear cell renal cell carcinoma, weakens the anti-tumor function of lncRNA-LET [12]. Notwithstanding, miR-373-3p’s role in HCC remains a puzzle.

Transcription factor activating enhancer binding protein 4 (TFAP4), situated at chromosome 16 p13. 3, modulates cell cycle, aging, and epithelial-mesenchymal transformation (EMT), etc. The aberrant profile of TFAP4 pertains to tumor occurrence and growth. Overexpression of TFAP4 upregulates lncRNA TRERNA1 to enhance gastric cancer cell migration and invasion [13]. Similarly, TFAP4 overexpression has the potential to elicit colorectal carcinoma (CRC) and can function as an indicator of poor prognosis [14]. TFAP4 activates the PI3K/AKT signal pathway, hence boosting tumor invasion and metastasis in liver cancer [15]. PI3K/AKT pathway inhibition exerts an antitumor function in HCC [16-18]. Nonetheless, whether the TFAP4/PI3K/AKT axis takes part in HCC development remains poorly understood.

Here, we discovered that miR-373-3p was downregulated in HCC, and the in vitro experiments denoted that miR-373-3p could substantially hamper HCC proliferation, migration, and invasion and facilitate apoptosis. Interestingly, miR-373-3p restrained TFAP4 expression and PI3K/Akt pathway activation in the context of HCC. Therefore, we guessed that miR-373-3p functioned as an anti-tumor gene in HCC by targeting TFAP4.

Materials and methods

Tissue samples

Thirty-two HCC patients were selected from the First Affiliated Hospital of Anhui Medical University as experimental samples, with their HCC tissues and paired adjacent normal tissues collected. After surgical resection, all the tissue samples were immediately kept in liquid nitrogen at −80°C until the experiment began. The pathological department of our hospital confirmed the samples. The study had received the imprimatur from the ethics committee of our hospital, and the participants had signed the informed content. The profile of miR-373-3p in the tumor samples was evaluated by qRT-PCR. miR-373-3p’s expression higher than 0.8 was defined as a high expression, otherwise as a low expression.

Cell culture and transfection

The European Collection of Cell Culture (ECACC, Salisbury, UK) supplied us with the normal human thyroid epithelial cell line L-02, while HCC cells (Huh7, HLE, HCCLM6, HCCLM3) were ordered from the College of Science, Institute of Cell Research, Chinese Academy of Sciences (Shanghai, China). The cells were cultivated with an RPMI-1640 complete medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Thermo Scientific Hyclone, Utah, USA) in an incubator (37°C, 5% CO2). The experiment was launched when the cells covered about 90% of the bottle bottom.

Huh7 and HCCLM3 cells underwent 0.25% trypsinization and were seeded on 6-well plates (1 × 105 cells per well). The oligonucleotides of miR-373-3p mimics and their nonspecific controls were bought from RiboBio (Guangzhou, China). Lentiviral vectors incorporating miR-373-3p (Lv-miR-373-3p) were synthesized in cells to represent miR-373-3p overexpression. When the cells achieved 70%–80% fusion, Lipofectamine® 3000 (Life Technologies, San Diego, CA, USA) was utilized to transfect Lv-miR-373-3p and the nonspecific control (Lv-NC), TFAP4 overexpression plasmids (TFAP4), small interfering RNA against TFAP4 (si-TFAP4), si-IGF1, and the corresponding negative control (vector, or si-NC) were transfected into the cells. All transfection steps were conducted as instructed by the supplier [19].

qRT-PCR

TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was taken to extract the total RNA of each group, with the RNA concentration determined. The RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) was manipulated to reverse-transcribe the miRNA, and miR-373-3p expression was verified. The total RNA was reversely transcribed into cDNA to determine the mRNA profile of TFAP4 as per the instructions of the TaKaRa kit (TaKaRa Bio Inc, Japan). Reaction conditions were as follows: 30 seconds’ pre-denaturation at 95°C, 5 seconds’ denaturation at 95°C-, and 30-seconds’ annealing/extending at 60°C, with 40 cycles in total. The 2−∆∆CT method was introduced to calculate the relative profile of the target gene [20]. The primer sequences of each molecule are detailed in Table 2.

Table 2.

Primer sequences of each molecule

Gene name Primer sequencesmiR-373-3p Forward: 5ʹ-GGCGGAAGTGCTTCGATTTT-3ʹ Reverse: 5ʹ-GTGCAGGGTCCGAGGTATTC-3ʹ

TFAP4 Forward: 5ʹ-GTGCCCACTCAGAAGGTGC-3ʹ Reverse: 5ʹ-GGCTACAGAGCCCTCCTATCA-3ʹIGF1 Forward: 5ʹ-TCTGAATCTTGGCTGCTGGA −3ʹ Reverse: 5ʹ-TGTGCTTCTTGACGACTTGC −3ʹIGF-1 R Forward: 5ʹ-AATTGCCACAAGTCCAGCTG −3ʹ Reverse: 5ʹ-CAGCCTTGGATGAACGATGG −3ʹ

GAPDH Forward: 5ʹ-ACAACTTTGGTATCGTGGAAGG-3ʹ Reverse: 5ʹ-GCCATCACGCCACAGTTTC-3ʹU6 Forward: 5ʹ-ATTGGAACGATACAGAGAAGATT-3ʹ Reverse: 5ʹ-GGAACGCTTCACGAATTTG-3ʹ

Flow cytometry

We took steadily transfected Huh7 and HCCLM3 cells and employed the Annexin V-FITC/PI staining kit (Yeasen Biotech Co., Ltd. Shanghai) to track apoptosis. Then, cold PBS was applied to flush the cells, and the binding buffer (100 mmol/L NaCl, 25 mmol/L CaCl2, 100 mmol/L HEPES, pH 7.4) was taken for cell resuspension. Annexin V-FITC/PI staining was implemented in the dark (room temperature, 15 min), and the apoptosis rate was assessed by FACS flow cytometry (Beckman Coulter, USA) [21].

Transwell assay

In an RPMI-1640 medium, the stably transfected cells were subjected to trypsinization and re-suspension (1 × 105 cells/mL). The upper Transwell chamber (8 μm) was filled with 200 μL cell suspension, and the lower compartment with an RPMI-1640 medium (500 μL) incorporating 10% fetal bovine serum. Afterward, the cells were incubated for 48 h (37°C, 5% CO2). The chambers were taken out, immobilized with 4% formaldehyde for 15 min, and dyed with 0.1% crystal violet solution for 5 min. After the residual crystal violet was cleaned with PBS, the cells without membrane penetration in the upper room were wiped off with caution. Finally, a microscope (Olympus, Japan) was exploited to count the cells in randomly chosen fields. For evaluating cell invasion, the chambers were pre-coated with a layer of Matrigel (BD company), and the other steps were the same of Transwell migration assay [22].

Western blot

RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China) was taken to lyse the cells, and the BCA protein determination kit (Thermo Fisher Scientific) was applied to determine the protein concentration. Next, 30 μg of the total protein was added to 12% polyacrylamide gel for 2 h’ 100 V electrophoresis and electrically moved onto PVDF membranes (Millipore, Bedford, MA, USA). After being sealed with 5% skimmed milk powder (room temperature, 1 h) and flushed with TBST three times (10 min each time), the membranes were incubated overnight along with primary antibodies anti-Bax antibody (ab32503), anti-Bcl2 antibody (ab117115), anti-Caspase 3 antibody (ab32351). Anti-E-cadherin antibody (ab40772), anti-vimentin antibody (ab8069), anti-Snail antibody (ab53519), anti-GAPDH antibody (ab181602), anti-PI3K antibody (ab32089), anti-PI3K (phospho) antibody (ab182651). Anti-AKT antibody (ab32505), anti-AKT (phospho) antibody (ab38449), anti-TFAP4 antibody (ab223771), anti-IGF1 (ab133542), anti-p-IGF1R (PA5-104,774, Thermo Fisher), and anti-IGF1R (ab182408) at 4°C. All those antibodies were supplied by Abcam (USA). Following TBST washing, the membranes were incubated along with horseradish peroxidase (HRP)-labeled Goat Anti-Rabbit IgG (1:300, ab6721, Abcam, USA) (room temperature, 1 h). TBST was utilized to rinse the membranes 3 times, 10 min each. ECL (Merck Millipore, MA, USA) was harnessed to expose protein bands [23].

Tumorigenesis in nude mice

Nude mice on a BALB/c background (4–6 weeks old) were acquired from the Experimental Animal Center at Huazhong University of Science and adopted to engineer a tumor model in vivo. Huh7 cells stably transfected with miR-373-3p were adjusted to a cell concentration of 2 × 107 mL-1. A total of 10 mice were injected subcutaneously in the right posterior axillary armpit with 0.1 ml cell suspension for each. In the next 5-week incubation, we monitored the survival rate, weight, and survival state of the mice. Since the 14th day, the tumor volume was gauged once every 4 days (volume = length to diameter × short diameter 2/2). Five weeks later, the mice were put to death, with their tumors harvested for weight measurement. The KI67 Cell Proliferation Kit (IHC) (Cat. no. E607235, Sangon Biotech (Shanghai) Co., Ltd.) was manipulated to examine Huh7 cell proliferation in line with the protocol. This animal experiment had received the green light from the Ethics Committee of The First Affiliated Hospital of Anhui Medical University and was implemented strictly in keeping with the guidelines of experimental animal care and use (NIH Publication No. 85-23201-1, National Institutes of Health, USA) [24].

Tissue immunofluorescence

The tumor tissues of the nude mice were routinely embedded in paraffin, sectioned (4 μm), deparaffinized with xylene, hydrated with gradient alcohol, and treated with 3% H2O2 for 30 min. At 4°C, the slices were incubated along with anti-PI3K (phospho) antibody (ab182651, 1:100, Abcam, USA) and anti-AKT (phospho) antibody (ab38449, 1:100, Abcam, USA) overnight. After that, the slices were flushed with PBS three times and then incubated along with Goat Anti-Rabbit IgG H&L (Alexa Fluor® 555) (ab150078) at 37°C for an hour. The nucleus was dyed using DAPI (Beyotime, Shanghai, China). At last, a fluorescence microscope (Olympus, Japan) was exploited to monitor the immunofluorescence signal [25].

Dual luciferase activity assay

Huh7 and HCCLM3 cells were inoculated into 24-well plates. With the use of Lipofectamine® 3000 (Life Technologies, San Diego, CA, USA), the TFAP4-WT and TFAP4-MUT reporter gene plasmids were co-transfected with miR-NC or miR-373-3p into the cells. Seventy-two hours subsequent to the transfection, an enzyme marker was taken to evaluate the activities of firefly luciferase and sea kidney luciferase in each group. The operation was carried out in strict accordance with the luciferase assay kit’s instructions (Promega, Madison, USA), and the ratio of firefly fluorescence intensity to sea kidney fluorescence intensity was adopted to reflect the relative fluorescence intensity of each group [26].

RNA immunoprecipitation (RIP) assay

The Magna RIP kit (Millipore, Billerica, MA, USA) was applied for RIP analysis. Following cell lysis with RIPA (Beyotime Biotechnology, Shanghai, China), the cell lysates obtained from Huh7 and HCCLM3 cells were incubated along with the RIP immunoprecipitation buffer (supplemented with the antibody Ago2, anti-mouse IgG, and protein A/G bead) at 4°C for an hour. TRIzol was employed for RNA extraction. RT-PCR was done to analyze the samples [27].

MTT assay

HCC cells (Huh7, HCCLM3, HL3, HCCLM6) steadily transfected were inoculated into 96-well plates (density: 2.5 × 103), with cell viability assessed via MTT (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). After Day 1, Day 2, Day 3, and Day 4, 10 µL of MTT (0.5 mg/mL) was administered to each well for 3 hours’ culture. Next, each well was given 250 µL of dimethyl sulfoxide. A microplate reader (Molecular Devices, LLC, Sunnyvale, CA, USA) was exploited to gauge the absorbance at 490 nm [28].

Data analysis

The GraphPad Prism 6 Software (GraphPad Software Inc., San Diego, CA, USA) was applied for analysis. The outcomes were presented as mean ± standard deviation (x ± s). Univariate ANOVA was taken for multi-factor comparison, while an independent sample t-test was for the comparison between two groups. Pearson correlation analysis was implemented to verify the correlation between the profiles of miR-373-3p and TFAP4. P < 0.05 was regarded as statistically meaningful.

Results

miR-373-3p expression in HCC

qRT-PCR evaluated miR-373-3p’s expression in HCC tissues and cells. In contrast to the adjacent normal tissues, miR-373-3p’s expression in HCC tissues was lower (P < 0.05, Figure 1(a)). Its expression in a couple of HCC cell lines (Huh7, HLE, HCCLM6, HCCLM3) was also lower than in the normal liver cell line L-02 (P < 0.05, Figure 1(b)). Survival analysis disclosed that the survival rate of HCC patients with high miR-373-3p expression was notably higher than those with a low expression of miR-373-3p (P = 0.034, Figure 1(c)). An analysis of the clinical characteristics illustrated that the lower miR-373-3p expression was, the worse the stage of tumor was, the more significant lymph node metastasis was (Table 1). Through the online database Kaplan–Meier Plotter (http://kmplot.com/analysis/), we found that those liver cancer patients with lower miR-373 level had poorer overall survival (OS) (P = 0.0013) and disease-free survival (DFS) (P = 0.005) (Figure 1(d-e)). This finding indicated that miR-373-3p expression was lowly expressed in HCC and was associated with patients’ prognosis as a favorable biomarker.

Figure 1.

miR-373-3p’s expression in HCC.

Table 1.

The relationship between the expression level of miR-373-3p and the clinical characteristics of HCC patients’ tissue specimens

Variable	miR-373-3p expression		P-value
	Low (n = 21)	High (n = 11)
Age (years)<50>50	138	56	0.372
GenderMaleFemale	516	38	0.830
Tumor size (cm)<5≥5	714	74	0.103
TNM stageI~ –IIIII–IV	912	92	0.039*
Lymph node metastasisNoYes	615	83	0.019*

Note: *P < 0.05 was statistically significant.

miR-373-3p boosted apoptosis and suppressed metastasis in HCC cells

To determine the influence of miR-373-3p on HCC progression, we transfected miR-373-3p mimics into Huh7 and HCCLM3 cell lines to overexpress miR-373-3p in preparation for in vitro experiments (P < 0.05, Figure 2(a)). MTT checked the viability of HCC cells (Huh7, HCCLM3, HL3, HCCLM6), signaling that miR-373-3p overexpression brought about a prominent decline in their viability (P < 0.05, Figure 2(b-e)). Flow cytometry unveiled that miR-373-3p overexpression substantially expanded HCC cell apoptosis (P < 0.05, Figure 2(f)). Colony formation assay examined cell proliferation, suggesting a remarkable decrease in the proliferation of HCC cells with miR-373-3p overexpression (P < 0.05, Figure 2(g)). The cell morphology in the miR-373-3p group showed enhanced cell junctions (Figure 2(h)). Transwell assay revealed that miR-373-3p overexpression vigorously hampered cell migration and invasion (P < 0.05, Figure 2(i)). The levels of apoptosis-concerned proteins (Bax, Bcl2, caspase 3) and EMT-correlated markers (E-cadherin, vimentin, Snail) were further examined via Western blot. By contrast to the miR-NC group, miR-373-3p overexpression considerably heightened Bax and caspase 3 expressions and restrained Bcl2’s expression (P < 0.05, Figure 2(j)). Vimentin and Snail expressions were much lower in the miR-373-3p group as opposed to the miR-NC group, while E-cadherin’s expression was uplifted (P < 0.05, Figure 2(k)). These findings manifested that miR-373-3p upregulation could mitigate HCC progression.

Figure 2.

miR-373-3p enhanced HCC cells’ apoptosis and suppressed their metastasis.

MiR-373-3p impeded tumor growth and accelerated the apoptosis in vivo

An in-vivo experiment was performed to reveal the impact of miR-373-3p on HCC. Huh7 cells were transfected along with miR-373-3p mimics or miR-NC and then subcutaneously transfused into the nude mice. The tumor size and weight were measured. As the data displayed, Lv-miR-373-3p substantially repressed the transplanted tumors (P < 0.05, Figure 3 A-C). IHC examined cell growth, indicating that miR-373-3p overexpression markedly attenuated the positive rate of KI-67 (Figure 3(d)). Western blot ascertained the profiles of apoptosis-concerned proteins in tumors in vivo. The statistics demonstrated that in contrast to the mere subcutaneous transfusion of Huh7 cells, Bax and caspase 3 expressions were elevated, and Bcl2’s expression was lowered in the tumors transfected with Lv-miR-373-3p cells (P < 0.05, Figure 3(e)). E-cadherin expression was enhanced, whereas vimentin and Snail expressions were lessened in the Lv-miR-373-3p group (P < 0.05, Figure 3(f)). The above discoveries further confirmed that miR-373-3p upregulation frustrated HCC growth in vivo and facilitated its apoptosis.

Figure 3.

miR-373-3p hampered tumor growth and boosted apoptosis in vivo.

miR-373-3p hindered PI3K/AKT pathway activation both in vivo and in vitro

To go into the downstream mechanism of miR-373-3p in HCC, we analyzed the co-expression genes of miR-373-3p in GC via the LinkedOmics database (http://linkedomics.org/login.php) and discovered the top 50 positive co-expression genes and the top 50 negative ones of miR-373-3p in GC (Figure 4(a)). With the assistance of the database, all these co-expression genes in HCC were taken for Gene Set Enrichment Analysis (GSEA). The outcome was that the PI3K/AKT pathway was negatively associated with miR-373-3p (Figure 4(b)). Western blot reflected that in contrast to the control group, p-PI3K and p-AKT expressions were considerably lowered following the transfection of miR-373-3p mimics in HCC cells (P < 0.05, Figure 4(c)). In in vivo experiments, p-PI3K and p-AKT expressions were attenuated in the Lv-miR-373-3p group, remarkably lower than in the control group (P < 0.05, Figure 4(d-e)). Tissue immunofluorescence analyzed the profile of PI3K/AKT in HCC, denoting that p-PI3K and p-AKT expressions were prominently brought down in the Lv-miR-373-3p group as compared with the control group (P < 0.05, Figure 4(f)). The outcomes unraveled that miR-373-3p upregulation suppressed PI3K/AKT pathway activation in vitro and in vivo.

Figure 4.

miR-373-3p dampened the PI3K/AKT pathway in vitro and in vivo.

miR-373-3p targeted TFAP4

Aiming at uncovering the downstream target of miR-373-3p, the StarBase database (http://starbase.sysu.edu.cn/) was adopted for predicting the targets of miR-373-3p. The result showed the binding complementary sites between TFAP4 and miR-373-3p (Figure 5(a)). Dual luciferase activity assay illustrated that miR-373-3p restrained the luciferase activity of TFAP4-WT cells but exerted little inhibitory influence on TFAP4-MUT cells (P > 0.05, Figure 5(b-c)). RIP assay demonstrated that the precipitation of TFAP4 in anti-Ago2 group was much more than that of IgG in HCC cells following overexpression of miR-373-3p (P < 0.05, Figure 5(d-e)). Pearson correlation analysis disclosed that miR-373-3p negatively correlated with TFAP4’s expression (P < 0.05, Figure 5(f)). qRT-PCR evaluated TFAP4 expression, signifying that it was much higher in HCC tissues and cells than in para-carcinoma normal tissues and the normal liver cell line L-02 (P < 0.05, Figure 5(g-h)). miR-373-3p transfection evidently abated TFAP4’s mRNA expression (compared to the miR-NC group) (P < 0.05, Figure 5(i)). These phenomena fully unveiled that miR-373-3p targeted and cramped the profile of TFAP4.

Figure 5.

miR-373-3p targeted TFAP4.

TFAP4 impeded cell apoptosis, bolstered metastasis, and initiated the PI3K/AKT pathway

To clarify the function of TFAP4 in HCC, we transfected TFAP4 overexpression plasmid into Huh7 cells (Figure 6(a)). Then, TFAP4 overexpression plasmids and, or miR-373-3p mimics were transfected into Huh7 cells. WB result indicated miR-373-3p attenuated TFAP4 protein level (compared with Con group or TFAP4 group, P < 0.05, Figure 6(b)). MTT checked cell viability, exhibiting that TFAP4 overexpression vigorously strengthened cell viability, whereas it was impaired when miR-373-3p was overexpressed following TFAP4 overexpression (P < 0.05, Figure 6(c)). Flow cytometry tracked apoptosis and reflected that miR-373-3p boosted apoptosis. Instead, the miR-373-3p+TFAP4 group witnessed a reduction in apoptosis (P < 0.05 compared with miR-373-3p group, Figure 6(d-e)). Followed by TFAP4 overexpression, the Huh7 cell injunction was reduced, and Huh7 cell tended to have interstitial cell morphology (Figure 6(f)). HCC cell migration and invasion were analyzed by Transwell assay. As a result, miR-373-3p lessened migration and invasion, but the miR-373-3p+TFAP4 group manifested expanded migration and invasion (P < 0.05, Figure 6(g)). Western blot unraveled that TFAP4 overexpression attenuated Bax and caspase 3 expressions and augmented Bcl2’s expression (P < 0.05, Figure 6(h)). As for EMT-associated markers, E-cadherin expression was lowered, whereas vimentin and Snail expressions were elevated in the miR-373-3p+TFAP4 group (as opposed to the miR-373-3p group, P < 0.05, Figure 6(i)). TFAP4 overexpression following miR-373-3p upregulation inactivated the PI3K/AKT pathway (P < 0.05, Figure 6(j)). These findings exhibited that TFAP4 upended the inhibitory function of miR-373-3p in HCC via PI3K/AKT pathway activation.

Figure 6.

TFAP4 suppressed cell apoptosis, boosted metastasis, and initiated the PI3K/AKT pathway.

IGF1 downregulation or PI3K/AKT inhibition attenuated the activating function of TFAP4 in the PI3K/AKT pathway

To further corroborate the mechanism of miR-373-3p/TFAP4 axis in HCC, we transfected HCC cells with si-IGF1 or dealt HCC cells with PI3K inhibitor LY294002 following TFAP4 overexpression. qRT-PCR and Western blot determined IGF1/IGF1R/PI3K/AKT expression, respectively. It emerged that overexpression of TFAP4 enhanced the profiles of IGF1, IGF1R, p-PI3K, and p-AKT. In contrast to the TFAP4 group, si-IGF1 conspicuously dampened their expressions, whereas LY294002 exerted little influence on IGF1 and IGF1R expressions, but lowered PI3K and AKT expressions (P < 0.05, Figure 7(a-d)). With a TFAP4 knockdown model engineered in Huh7 cells, Western blot confirmed the profile of TFAP4. The experiment displayed that TFAP4 knockdown distinctly abated its expression (P <0.05, Figure 7(e)). miR-373-3p was overexpressed after TFAP4 knockdown, and Western blot was implemented to verify the profiles of IGF1/IGF1R/PI3K/AKT. It revealed that TFAP4 knockdown or miR-373-3p overexpression curbed their profiles (P < 0.05, Figure 7(f-h)), but no substantial alterations were seen in the si-TFAP4+ miR-373-3p group (compared to the si-TFAP4 group) (P <0.05, Figure 7(f-i)). These findings reflected that miR-373-3p hampered the IGF1/IGF1R/PI3K/AKT pathway to display its anti-cancer function in HCC by directly targeting TFAP4 (Figure 8).

Figure 7.

IGF1/IGF1R or PI3K/AKT inhibition attenuated the activating function of TFAP4 in the PI3K/AKT pathway.

Figure 8.

The mechanism’s diagram.

Discussion

Primary liver cancer has become the second biggest contributor to cancer-correlated death worldwide. The incidence rate of liver cancer has been on the rise in recent years [29,30]. Hepatocarcinogenesis is a long-term accumulation course concerning a variety of aberrant biological processes. Its precancerous lesions feature chronic liver injury, small cell dysplasia, necrotizing inflammation, and nodule regeneration [31]. miRNAs can influence HCC development through multiple biological processes. Here, we discovered that miR-373-3p suppressed HCC cell proliferation and metastasis by modulating the TFAP4/PI3K/AKT axis (Figure 8).

MicroRNAs, short single-stranded RNAs, often modulate gene expressions at the transcription level through their combination with the target mRNA 3ʹUTR, thus degrading genes or hobbling translation [32]. miR-361-5p targets Twist1 and cramps HCC cell proliferation, migration, invasion, and tumor growth [33]. miR-631 targets PTPRE to dampen HCC migration, invasion, EMT, and intrahepatic metastasis [34]. Similar effects on liver cancer are also reflected in the other miRNAs like miR-199a-3p [35], miR-124-3p [36], and miR-216a-3p [37]. miR-373-3p is a novel miRNA first uncovered by Syring et al. Its expression is substantially heightened in the serum of patients suffering from testicular germ cell tumors [38]. miR-373-3p targeting LATS2 and OXR1 enhances esophageal squamous cell carcinoma progression, and its expression was vigorously attenuated in the serum of patients with tumor resection [39]. miR-373-3p has also been discovered to boast the function of repressing malignancies. For instance, miR-373-3p, downregulated in the gemcitabine resistant pancreatic cancer cell line (GEM-PANC-1), targets CCND2 to conspicuously suppress GEM-PANC-1 cells’ proliferation and invasion, boost their apoptosis, and strengthen their sensitivity to gemcitabine [40]. miR-373-3p is notably downregulated in septicemia-triggered acute liver injury, and miR-373-3p mimics can curb hepatocyte apoptosis and augment cell viability [41], indicating that miR-373-3p also carries the function of defending hepatocytes. We boldly speculate that miR-373-3p exerts an inhibitory impact on liver cancer. Our experiments displayed that miR-373-3p was downregulated in liver cancer tissues and cells, and patients with a high profile of miR-373-3p enjoyed a better survival prognosis. miR-373-3p upregulation could not only facilitate apoptosis but also hamper migration and EMT. Our observation denoted that miR-373-3p could be utilized as a tumor suppressor in HCC.

TFAP4, a transcription factor derived from the helical link-helical leucine zipper (bHLH-LZ) family, is extensively expressed in human tissues. Cell proliferation, migration, and invasion are the primary features of cancer. TFAP4 has been disclosed to partake in malignant tumor differentiation, metastasis, and angiogenesis [42]. TFAP4 activates the Wnt/β-catenin pathway to exert its carcinogenic function in liver cancer [43]. TFAP4 knockdown selectively hinders MYCN-elicited neuroblastoma growth both in vitro and in vivo [44]. Of note, TFAP4, a downstream target of some miRNAs, is negatively modulated by miRNAs, thereby participating in tumor suppression. For instance, miR-608 represses TFAP4’s expression to boost non-small cell lung cancer apoptosis [45]. miR-302 c targets TFAP4 to frustrate colorectal cancer metastasis and EMT [46]. Notwithstanding, whether the miR-373-3p/TFAP4 axis partakes in HCC and its exact mechanism still obfuscates us. Through biological information analysis, we have discovered that miR-373-3p targets and negatively modulates TFAP4, and TFAP4 overexpression markedly inverts the inhibitory function mediated by miR-373-3p in HCC cells.

PI3K primarily influences cell proliferation and apoptosis. AKT, a downstream effector of PI3K, is usually initiated by PI3K and participates in cell proliferation, invasion, EMT and other processes [47]. PI3K/AKT, often activated in malignant tumors, is recognized as a critical signaling pathway of the anti-tumor mechanism, which is often negatively modulated by miRNAs. miR-1254 targets Smurf1 to frustrate PI3K/AKT pathway activation, thereby suppressing gastric cancer proliferation, metastasis, and EMT [48]. Integrin 6 (ITGA6), targeted by miR-143-3p, impedes the PI3K/AKT pathway to elicit gallbladder cancer growth and angiogenesis [49]. Moreover, targeting IGF-1 R, the upstream molecular of PI3K/AKT pathway, also leads to tumor inhibiting by inactivating PI3K/AKT pathway [50]. TFAP4 initiates the PI3K/AKT pathway to step up liver cancer development [11]. Here, we found that TFAP4 promotes IGF1 expression, induces IGF-1 R, PI3K and AKT phosphorylation. However, miR-373-3p restrains TFAP4 and IGF1 expression, thus inactivating IGF-1 R/PI3K/AKT pathway. Hence, the miR-373-3p/TFAP4/PI3K/AKT makes a role in influencing HCC progression.

Conclusion

Collectively, miR-373-3p’s expression is lowered in HCC, and miR-373-3p overexpression boosts apoptosis and hampers migration and EMT. miR-373-3p targets TFAP4 and cramps the IGF1/IGF-1 R/PI3K/AKT signaling pathway (Figure 8). Our paper provides impetus and direction for the development of novel HCC prognostic markers and treatment strategies, but further in-depth studies are still needed to substantiate their clinical feasibility.